• 6 min read
• Published on 13 January 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
I’ve been watching the stock market long enough to know a genuine sea change from a passing fad. And let me tell you, what’s happening in the pharmaceutical world right now feels like the real deal. For decades, drug discovery has been a bit like trying to find a specific grain of sand on a very large beach. It’s slow, mind-numbingly expensive, and more often than not, you go home empty-handed. But now, big pharma thinks it's found a metal detector, and it's called artificial intelligence.
When a company like NVIDIA, the brains behind the AI computing boom, teams up with a pharmaceutical titan like Eli Lilly to the tune of one billion dollars, you have to sit up and pay attention. That isn't just a research grant. It's a statement of intent. They’re betting the farm that algorithms can succeed where legions of scientists in white coats have struggled for years.
Think about it. The traditional path to getting a new medicine on the pharmacy shelf can take up to fifteen years and burn through billions of pounds. For every one drug that makes it, nine others fail spectacularly along the way. It’s a business model that seems almost designed for failure. AI promises to turn this on its head. Instead of manually testing compounds, a machine can analyse millions of them in a weekend. It could predict side effects before a single human trial begins, saving fortunes and, more importantly, time.
This isn’t just about one flashy partnership, though. The entire ecosystem is shifting. You have companies like NVIDIA, which I see as the modern-day equivalent of selling shovels during a gold rush. They don’t care which drug succeeds, as long as everyone uses their powerful computer chips to do the digging.
Then you have the established players, the Eli Lillys of the world. They’re wisely choosing to embrace the disruption rather than be run over by it. They bring the institutional knowledge, the regulatory know-how, and the vast libraries of existing drug data. Finally, you’ve got the nimble biotech firms like Regeneron, which are already weaving this computational approach into their very DNA. To me, it’s a fascinating three-way race, and it’s not yet clear who will come out on top.
Of course, the science behind all this sounds terribly clever. Computational biology and precision medicine are the buzzwords of the day. The goal is to move away from a one-size-fits-all approach to medicine and towards treatments designed for an individual’s unique genetic makeup. The commercial logic is undeniable. A bespoke medicine that works wonders can command a high price, and if AI can slash the development costs, the profit margins could be quite handsome.
This convergence of biology and technology has created a fascinating new field for investors to explore. You can see a collection of these companies in the AI Drug Discovery | Biotech Investment Opportunities basket, which lumps together the tech titans and the biotech hopefuls. It is an interesting way to look at the sector as a whole.
However, let’s not get carried away. Investing in this area isn’t for the faint of heart. Biology is messy, and the human body has a wonderful habit of not behaving as the computer models predict. Regulatory bodies are cautious by nature, and they’re still getting their heads around how to approve a drug that was designed by an algorithm. While the potential rewards are significant, the risks remain very real. It's a punt, but it might just be one of the most calculated and potentially transformative punts of the decade.
View the full Basket:AI Drug Discovery | Biotech Investment Opportunities
View the full Basket:AI Drug Discovery | Biotech Investment Opportunities
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article